Day One Biopharmaceuticals I(DAWN)
$14.06▲1.88%
Insights
- Day One Biopharmaceuticals I is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Day One Biopharmaceuticals I stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Day One Biopharmaceuticals I stock is Range bound.
- Based on analysis of the Pivot Points, the current market trend for Day One Biopharmaceuticals I stock suggests that it is a good time to sell or bad time to initiate a fresh position
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 47.77 | Neutral |
Stochastic | 26.32, 41.1 | Neutral |
Ultimate Oscillator | 45.43 | Neutral |
Stochastic Relative Strength Index | 37.1, 42.08 | Neutral |
Moving Average Convergence Divergence | 0.03, 0.03 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 14.17 | Buy |
20 | 14.09 | Sell |
50 | 14.14 | Sell |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 14.13 | Buy |
20 | 14.11 | Sell |
50 | 14.16 | Sell |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 14.23 | Neutral |
20 | 14.12 | Neutral |
50 | 14.27 | Neutral |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 14.15 | Buy |
20 | 14.14 | Buy |
50 | 13.91 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 14.12 | Sell |
20 | 14.2 | Buy |
50 | 14.13 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 14.9 |
Resistance L2 | 14.7 |
Resistance L1 | 14.43 |
Pivot Point | 14.22 |
Support L1 | 13.95 |
Support L2 | 13.75 |
Support L3 | 13.48 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.